Now anyone who is obese as defined by body mass index (BMI) or who is overweight per BMI and has at least one weight-related health condition is eligible for a GLP-1 prescription
Interestingly, they found aberrations in ROS clearance pathways, including elevated glutathione levels, decreases in mitochondrial superoxide dismutase levels, and glutathione peroxidase 4 mediated lipid oxidative damage
(Some interpret that if the patient has a co-occurring psychiatric diagnosis, it fits the psychiatric treatment exception but this is legally murky and risky without clear guidance.) The good news: GLP-1 agonists like semaglutide are not controlled substances , so they can be prescribed via Florida telehealth as long as you meet the states obesity treatment standards (BMI documentation, informed consent, quarterly follow-ups)
Access ongoing coaching and tracking tools
Here's what typically sets medical programs apart: Clinician involvement: Board-certified providers review your health profile and guide treatment
In many model organisms, as well as in humans, it is difficult to detect the cannonical GLP-1 receptor in these tissues